Summary
Overview
Work History
Education
Skills
Patents
Selected Publications
Awards And Fellowships
Languages
Accomplishments
Work Preference
Interests
Timeline
Generic
Jer-Yuan (Arthur) Hsu

Jer-Yuan (Arthur) Hsu

San Bruno,USA

Summary

Accomplished scientific leader with extensive experience at NGM Biopharmaceuticals, driving drug discovery and development programs. Proven track record in resource optimization and cross-functional partnerships, delivering multiple IND candidates. Expertise in metabolism, oncology, and immunology research, complemented by strong project management and effective communication skills.

Overview

32
32
years of professional experience

Work History

Vice President, Biology

NGM Biopharmaceuticals
South San Francisco, CA
02.2025 - Current
  • Directed a team of 20 scientists in preclinical drug discovery and development programs.
  • Oversaw a portfolio of seven drug discovery programs to meet organizational objectives of delivering an IND candidate annually.
  • Collaborated with the Biologics Head to define the research direction and allocate resources.
  • Developed strategic plans to align research efforts with organizational goals.
  • Contributed to the Research Management group by providing input on research initiatives and operations.

Senior Director, Head of Biology

NGM Biopharmaceuticals
South San Francisco, CA
04.2023 - 01.2025
  • Led a team of 20 scientists, driving preclinical drug discovery and development efforts.
  • Achieved delivery of new IND candidate from a pipeline of five drug discovery programs.
  • Partnered with Biologics leadership to establish strategic research priorities and allocate resources effectively.
  • Developed strategic plans ensuring alignment of research initiatives with organizational goals.
  • Participated in weekly discussions regarding research operations within the Research Management group.

Research Fellow

NGM Biopharmaceuticals
South San Francisco, CA
02.2020 - 03.2023
  • Led drug discovery and development programs in oncology, autoimmunity, and cardiovascular diseases.
  • I served as the Project Team Lead for the interdisciplinary GDF15/GFRAL translational research team.
  • Acted as the Scientific Lead for Product Development Teams of clinical-stage candidates, NGM395 and NGM120.
  • Provided strategic insights as a member of the Discovery Research Diligence Group with the CSO, CTO, and department heads.
  • Directed cardiovascular research for the NGM-Merck joint program to advance collaborative initiatives.
  • Managed academic collaborations on the NGM immuno-oncology pipeline involving NGM707, NGM831, and NGM438.
  • Established consulting relationships with key opinion leaders at external institutions to enhance research efforts.
  • Facilitated cross-functional teamwork to ensure alignment across Biology, Toxicology, Pathology, and Clinical Development.

Principal Scientist

NGM Biopharmaceuticals
South San Francisco, CA
02.2017 - 01.2020
  • Directed discovery group comprising four Ph.D.s. Scientists and three research associates, including three project team leads.
  • Spearheaded discovery efforts for B7-H7/KIR3DL3, and the subsequent drug development program.
  • Contributed to drug discovery and the development of NGM831 through ILT3/Fibronectin interaction research.
  • Oversaw translational research activities for the GDF15 drug development program.
  • Advised senior management on strategic initiatives and project direction.
  • Managed collaborations with academic laboratories to enhance research outcomes.
  • Established consulting relationships with key opinion leaders to support development efforts.

Senior Scientist

NGM Biopharmaceuticals
South San Francisco, CA
02.2014 - 01.2017
  • Spearheaded GDF15 drug development program, yielding short-acting NGM386 and long-acting NGM395 IND candidates for metabolic diseases.
  • Directed GFRAL drug discovery program, delivering NGM120 as a candidate for cancer cachexia.
  • Established a high-throughput screening system for orphan receptor/ligand identification to enhance research capabilities.
  • Initiated an immuno-oncology target discovery effort to expand therapeutic options at NGM.
  • Managed collaborations with academic laboratories, advancing critical research objectives.
  • Cultivated consulting relationships with key opinion leaders to inform strategic program decisions.

Scientist II

NGM Biopharmaceuticals
South San Francisco, CA
11.2009 - 01.2014
  • Led the GDF15 drug discovery and development program, identifying GFRAL as the receptor for GDF15.
  • Uncovered the mechanism of action for GDF15 to enhance understanding of its therapeutic potential.
  • I served as the in vitro pharmacology lead for the FGF19 drug development program.
  • Developed in vitro efficacy assays for evaluating FGF19 lead candidates.
  • Established a drug release assay for the clinical candidate NGM282 (aldafermin).
  • Investigated mechanisms influencing FGF19's tumorigenicity and bile acid regulation.
  • Identified beneficial factors associated with bariatric surgery within the GI research program.

Project Scientist

University of California, San Diego
San Diego, CA
07.2006 - 11.2009
  • Project: Studies of molecular mechanisms of gene expression.
  • Functional analyses of novel DNA sequence elements that regulate gene expression.
  • Identification of core promoter-specific transcription factors.

Post Doctoral Fellow

University of California, San Diego
San Diego, CA
03.2002 - 06.2006
  • Supervisor: Dr. James T. Kadonaga.
  • Project: Analysis of gene expression at the level of transcription.
  • Investigated transcription regulation by transcription factors and chromatin remodeling factors.

PhD Student

University of Virginia
Charlottesville, VA
01.1998 - 01.2002
  • Thesis advisors: Drs. C. David Allis and M. Mitchell Smith.
  • Project: Regulation of histone phosphorylation, and genetic dissection of histone tail function.
  • Investigated the regulation and biology of histone phosphorylation in yeast.
  • Engineered a yeast strain for studying histone functions systematically.
  • Discovered and characterized novel genetic interactions between histone tails.

Masters Student

National Yang-Ming University, Taiwan
Taipei, Taiwan
09.1993 - 06.1995
  • Thesis advisor: Dr. Yi-Ming A. Chen.
  • Project: Identification of genes misregulated in human liver cancers.
  • Implemented the mRNA differential display technique to identify altered gene expressions in human liver cancers.
  • Discovered Glycine N-methyl Transferase (GNMT) as a gene that is downregulated in human liver cancers.

Education

Ph.D. - Biochemistry and Molecular Genetics

University of Virginia
Charlottesville, VA
01.2002

M.Sc. - Microbiology and Immunology

National Yang-Ming University
Taipei, Taiwan
06.1995

B.S. - Zoology

National Taiwan University
Taipei, Taiwan
06.1993

Skills

  • Scientific mentorship and leadership skills
  • Expertise in drug discovery and development processes
  • Project management proficiency
  • Teamwork and collaboration skills
  • Resource optimization strategies
  • Cross-functional partnership building
  • Data analysis capabilities
  • Effective communication techniques
  • Adaptability with problem-solving skills
  • Analytical skill set
  • Identification of novel drug targets
  • Research experience in immunology, oncology, and metabolism
  • In vivo and in vitro pharmacological studies
  • High-throughput screening expertise
  • Development of functional assays
  • Strategic planning acumen

Patents

  • Ilt3-binding agents and methods of use thereof, Suzanne Christine Crawley, Jer-Yuan Hsu, Daniel David Kaplan, Betty Chan Li, Vicky Yi-Bing Lin, Seth Malmersjö, Kevin James Paavola, Julie Michelle Roda, Yan Wang, US20210221887A1, 12/17/20
  • B7-h7-binding agents and methods of use thereof, Jer-Yuan Hsu, Suzanne Christine Crawley, WO2020041300A1, 08/21/18
  • Compositions and methods for modulating body weight, Jer-Yuan Hsu, Yu Chen, Suzanne Christine Crawley, Hui Tian, Wenyan Shen, Jie Tang, Jared Martin Higbee, WO2017152105A1, 03/04/16
  • Compositions and methods of use for treating metabolic disorders, Darrin Anthony Lindhout, Raj Haldankar, Hui Tian, Jer-Yuan Hsu, US20160031960A1, 07/30/14, 12/05/17

Selected Publications

  • The Fibronectin-ILT3 Interaction Establishes a Stromal Checkpoint that Suppresses Myeloid Cells, Paavola KJ, Roda JM, Lin VY, Chen P, O’Hollaren K, Ventura R, Crawley SC, Li B, Chen HH, Malmersjö S, Sharkov NA, Horner G, Guo W, Kutach AK, Mondal K, Zhang Z, Lichtman JS, Song C, Rivera LB, Liu W, Luo J, Wang Y, Solloway M, Allan BB, Kekatpure A, Starck SR, Haldankar R, Fan B, Chu C, Tang J, Molgora M, Colonna M, Kaplan DD, and Hsu JY, Cancer Immunology Research, 2021 (Corresponding author)
  • Antibody-mediated inhibition of GDF15-GFRAL activity reverses cancer cachexia in mice, Suriben R, Chen M, Higbee J, Oeffinger J, Ventura R, Li B, Mondal K, Gao Z, Ayupova D, Taskar P, Li D, Starck S, Chen HIH, McEntee M, Katewa SD, Phung V, Wang M, Kekatpure A, Lakshminarasimhan D, White A, Olland A, Haldankar R, Solloway MJ, Hsu JY, Wang Y, Tang J, Lindhout DA, Allan BB, Nature Medicine, 2020
  • Non-homeostatic body weight regulation through a brainstem-restricted receptor for GDF15, Hsu JY, Crawley S, Chen M, Ayupova DA, Lindhout DA, Higbee J, Kutach A, Joo W, Gao Z, Fu D, To C, Mondal K, Li B, Kekatpure A, Wang M, Laird T, Horner G, Chan J, McEntee M, Lopez M, Lakshminarasimhan D, White A, Wang SP, Yao J, Yie J, Matern H, Solloway M, Haldankar R, Parsons T, Tang J, Shen WD, Alice Chen Y, Tian H, Allan BB, Nature, 2017 (Co-corresponding author)
  • Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19, Zhou M, Wang X, Phung V, Lindhout DA, Mondal K, Hsu JY, Yang H, Humphrey M, Ding X, Arora T, Learned RM, Depaoli AM, Tian H, and Ling L, Cancer Research, 2014
  • Restoration of euglycemia after duodenal bypass surgery is reliant on central and peripheral inputs in Zucker fa/fa rats, Jiao J, Bae EJ, Bandyopadhyay G, Oliver J, Marathe C, Chen M, Hsu JY, Chen Y, Tian H, Olefsky JM, and Saberi M, Diabetes, 2013
  • Hsu JY, Juven-Gershon T, Marr II MT, Wright KJ, Tjian R, and Kadonaga JT. TBP, Mot1 and NC2 establish a regulatory circuit that controls DPE-dependent versus TATA-dependent transcription. Genes and Development, 2008.
  • Hsu JY, Sun ZW, Li X, Reuben M, Tatchell K, Bishop DK, Grushcow JM, Brame CJ, Caldwell JA, Hunt DF, Lin R, Smith MM, Allis CD. Mitotic phosphorylation of histone H3 is governed by Ipl1/aurora kinase and Glc7/PP1 phosphatase in budding yeast and nematodes. Cell, 2000.

Awards And Fellowships

  • Innovation Award, NGM Bio, 2015
  • Post-doctoral Fellowship, Helen Hay Whitney Foundation, 2003-2006
  • Studentship, Institute of Biomedical Sciences, Academia Sinica, Taiwan, 1993-1995
  • The President’s Award, National Taiwan University, 1993

Languages

English
Advanced (C1)
C1
Chinese (Mandarin)
Proficient (C2)
C2
Spanish
Elementary
A1

Accomplishments

Innovation Award, NGM Bio 2015

Post-doctoral Fellowship, Helen Hay Whitney Foundation 2003-2006

Studentship, Institute of Biomedical Sciences, Academia Sinica, Taiwan 1993-1995

The President’s Award, National Taiwan University 1993

Work Preference

Work Type

Full Time

Interests

Cycling, swimming, golfing, youth sports

Timeline

Vice President, Biology

NGM Biopharmaceuticals
02.2025 - Current

Senior Director, Head of Biology

NGM Biopharmaceuticals
04.2023 - 01.2025

Research Fellow

NGM Biopharmaceuticals
02.2020 - 03.2023

Principal Scientist

NGM Biopharmaceuticals
02.2017 - 01.2020

Senior Scientist

NGM Biopharmaceuticals
02.2014 - 01.2017

Scientist II

NGM Biopharmaceuticals
11.2009 - 01.2014

Project Scientist

University of California, San Diego
07.2006 - 11.2009

Post Doctoral Fellow

University of California, San Diego
03.2002 - 06.2006

PhD Student

University of Virginia
01.1998 - 01.2002

Masters Student

National Yang-Ming University, Taiwan
09.1993 - 06.1995

Ph.D. - Biochemistry and Molecular Genetics

University of Virginia

M.Sc. - Microbiology and Immunology

National Yang-Ming University

B.S. - Zoology

National Taiwan University
Jer-Yuan (Arthur) Hsu